- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07495943
Effekter av 2-Aticytokomplex och D-Ribos på smärta och klinisk förlopp hos patienter med fibromyalgi
Effekter av 2-Aticyto Complex och D-Ribos på smärta, symptom och klinisk förlopp hos patienter med fibromyalgi syndrom
This multicenter, randomized, double-blind, placebo-controlled study will evaluate whether an oral supplement containing 2-Aticyto Complex and D-ribose (FibroThol), added to ongoing standard medical treatment, improves pain, symptoms, and clinical course in adults with fibromyalgia syndrome. Eligible participants are adults aged 18 to 65 years who have had fibromyalgia for at least 1 year and have been receiving pregabalin and/or duloxetine for at least 3 months. Participants will be randomly assigned to receive either FibroThol or placebo, administered as 15 mL three times daily for 4 weeks, while continuing their existing treatment. Follow-up assessments will be performed at baseline, week 2, and week 4 using patient-reported symptom and function measures. The study aims to determine whether this supportive supplement provides additional benefit compared with placebo in patients with persistent symptoms despite standard therapy.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Fibromyalgia syndrome is a chronic condition associated with widespread pain, fatigue, sleep disturbance, and reduced quality of life. Although standard pharmacologic treatments such as pregabalin and duloxetine are commonly used, symptom control may remain incomplete in many patients. This study was designed to investigate whether adding a supplement containing 2-Aticyto Complex and D-ribose to ongoing standard treatment can improve clinical outcomes in adults with fibromyalgia syndrome.
This is a multicenter, randomized, double-blind, placebo-controlled clinical study. Adults aged 18 to 65 years with fibromyalgia syndrome, diagnosed according to the ACR 2016 criteria, followed for at least 1 year, and receiving pregabalin and/or duloxetine treatment for at least 3 months will be eligible for participation. Major exclusion criteria include rheumatologic disease, renal failure, hepatic failure, cardiovascular disease, diabetes or hypoglycemia, neurologic disease, use of other supplements, allergy to study product ingredients, inability to complete study procedures, or refusal to participate.
After eligibility assessment and informed consent, participants will be randomly assigned to one of two study groups: placebo plus ongoing standard treatment or FibroThol plus ongoing standard treatment. The study treatment will be administered orally at a dose of 15 mL three times daily for 4 weeks. Study visits and assessments will be performed at baseline, week 2, and week 4.
Outcome measures will include pain intensity, neuropathic pain, fibromyalgia-related functional status, fatigue, sleep quality, anxiety, and depression, assessed using validated clinical scales. Safety will be evaluated through adverse event monitoring during the study period.
A total of 200 participants will be enrolled, with 100 participants assigned to the FibroThol group and 100 participants assigned to the placebo group. The primary objective is to determine whether the addition of 2-Aticyto Complex and D-ribose to standard treatment provides additional benefit in reducing pain and improving symptoms and overall clinical course in patients with fibromyalgia syndrome.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Kubra Neslihan Kurt Oktay, MD
- Telefonnummer: +905352916609
- E-post: drneslihankurt@gmail.com
Studieorter
-
-
-
Istanbul, Turkiet (Türkiye), 34480
- University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Fatih Bagcıer, MD
- Telefonnummer: +905442429042
- E-post: bagcier_42@hotmail.com
-
Istanbul, Turkiet (Türkiye), 34668
- University of Health Sciences, Sultan Abdulhamid Han Training and Research Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Mustafa Hüseyin Temel, MD
- Telefonnummer: +905342714872
- E-post: mhuseyintemel@gmail.com
-
Underutredare:
- Emre Ata, MD
-
Istanbul, Turkiet (Türkiye), 34732
- Erenkoy Physical Therapy and Rehabilitation Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Sefa Kurt, MD
- Telefonnummer: +905385159528
- E-post: sefa.kurt@yahoo.com
-
Istanbul, Turkiet (Türkiye), 34752
- University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Ozge Gulsum Illeez, MD
- Telefonnummer: +905326255684
- E-post: ozgeilleez@gmail.com
-
-
Istanbul
-
Istanbul, Istanbul, Turkiet (Türkiye), 34662
- University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Kubra Neslihan Kurt Oktay, MD
- Telefonnummer: +905352916609
- E-post: drneslihankurt@gmail.com
-
Underutredare:
- Arzu Erbilici, MD
-
Underutredare:
- Duygu Geler Kulcu, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Adults aged 18 to 65 years
- Diagnosis of fibromyalgia syndrome according to the 2016 ACR criteria
- Followed in a physical medicine and rehabilitation outpatient clinic for at least 1 year
- Receiving pregabalin and/or duloxetine treatment for at least 3 months
- Able to live independently in the community
- Literate and able to record symptoms and responses
- No cognitive dysfunction that would interfere with answering study questions
- Able and willing to provide informed consent
Exclusion Criteria:
- Rheumatologic disease
- Renal failure
- Hepatic failure
- Cardiovascular disease
- Hypoglycemia or diabetes mellitus
- Any neurologic disease (such as stroke, spinal cord injury, multiple sclerosis, or Parkinson's disease)
- Known allergy or hypersensitivity to any active or excipient component of the study syrup
- Use of any other dietary supplement or nutritional support product during the study period
- Pregnancy or lactation
- Active malignancy
- Active infection
- Severe psychiatric disease that may interfere with study participation or assessment
- Refusal to participate or inability to provide informed consent
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Placebo Plus Standard Treatment
Participants will receive matching placebo orally at 15 mL three times daily for 4 weeks, in addition to their ongoing standard medical treatment with pregabalin and/or duloxetine. |
A matching oral placebo syrup without active study ingredients. In this study, participants will receive 15 mL orally three times daily for 4 weeks in addition to ongoing standard treatment with pregabalin and/or duloxetine. The placebo contains deionized water, glycerol, sodium alginate, xanthan gum, steviol glycosides, raspberry flavor, pineapple flavor, strawberry flavor, and mint flavor. |
|
Experimentell: FibroThol Plus Standard Treatment
Participants will receive FibroThol, an oral supplement containing 2-Aticyto Complex and D-ribose, at 15 mL three times daily for 4 weeks, in addition to their ongoing standard medical treatment with pregabalin and/or duloxetine. |
An oral dietary supplement containing 2-Aticyto Complex and D-ribose (marketed as FibroThol). In this study, participants will receive 15 mL orally three times daily for 4 weeks in addition to ongoing standard treatment with pregabalin and/or duloxetine. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Pain Intensity Measured by Numeric Rating Scale (NRS)
Tidsram: Baseline, Week 2, and Week 4
|
Pain intensity will be assessed using the Numeric Rating Scale (NRS), an 11-point scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Neuropathic Pain Measured by DN4
Tidsram: Baseline, Week 2, and Week 4
|
Neuropathic pain symptoms will be assessed using the Douleur Neuropathique 4 (DN4) questionnaire, with a total score range of 0 to 10. Higher scores indicate more neuropathic pain features, and a score of 4 or more suggests neuropathic pain. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
|
Change in Fibromyalgia Impact Questionnaire Score
Tidsram: Baseline, Week 2, and Week 4
|
Participation limitations will be assessed using the Fibromyalgia Participation Questionnaire, with transformed scale values ranging from 0 to 100. Higher scores indicate better participation and social functioning, so an increase from baseline reflects improvement. |
Baseline, Week 2, and Week 4
|
|
Change in Fibromyalgia Participation Questionnaire Score
Tidsram: Baseline, Week 2, and Week 4
|
Fatigue severity will be assessed using the Fatigue Severity Scale, a 9-item scale with a total score range of 9 to 63. Higher scores indicate greater fatigue severity. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
|
Change in Fatigue Severity Scale (FSS) Score
Tidsram: Baseline, Week 2, and Week 4
|
Participation limitations will be assessed using the Fibromyalgia Participation Questionnaire, with transformed scale values ranging from 0 to 100. Higher scores indicate better participation and social functioning, so an increase from baseline reflects improvement. |
Baseline, Week 2, and Week 4
|
|
Change in Pittsburgh Sleep Quality Index (PSQI) Score
Tidsram: Baseline, Week 2, and Week 4
|
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index, with a global score range of 0 to 21. Higher scores indicate poorer sleep quality. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
|
Change in Beck Depression Inventory Score
Tidsram: Baseline, Week 2, and Week 4
|
Depressive symptoms will be assessed using the Beck Depression Inventory, a 21-item scale with a total score range of 0 to 63. Higher scores indicate more severe depressive symptoms. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
|
Change in Beck Anxiety Inventory Score
Tidsram: Baseline, Week 2, and Week 4
|
Anxiety symptoms will be assessed using the Beck Anxiety Inventory, a 21-item scale with a total score range of 0 to 63. Higher scores indicate more severe anxiety symptoms. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Kubra Neslihan Kurt Oktay, MD, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation
- Studiestol: Kubra Nesihan Kurt Oktay, MD, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation
Publikationer och användbara länkar
Allmänna publikationer
- Teitelbaum JE, Johnson C, St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med. 2006 Nov;12(9):857-62. doi: 10.1089/acm.2006.12.857.
- Teitelbaum J, Jandrain J, McGrew R. Treatment of Chronic Fatigue Syndrome and Fibromyalgia with D-Ribose- An Open-label, Multicenter Study. The Open Pain Journal. 2012;5:32-37.
- Kerget F, Kerget B, Aksakal A, Kocak AO. Can 2-Aticyto Complex be an Effective Agent for Recovery of The Symptoms and Enhancing Laboratory Parameters in COVID-19 Patients? European Journal of Medical and Health Sciences. 2021;3(2):35-39. doi:10.24018/ejmed.2021.3.2.745.
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Neurologiska manifestationer
- Muskuloskeletala sjukdomar
- Sjukdomar i nervsystemet
- Muskelsjukdomar
- Mentala störningar
- Neuromuskulära sjukdomar
- Reumatiska sjukdomar
- Beteendesymtom
- Vakna sömnstörningar
- Sömnstörningar, inneboende
- Dyssomni
- Patologiska tillstånd, tecken och symtom
- Beteende
- Tecken och symtom
- Smärta
- Ångeststörningar
- Fibromyalgi
- Depression
- Sömninitiering och underhållsstörningar
Andra studie-ID-nummer
- HNHAH-KAEK 2025/1
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Individual participant data will not be shared. Aggregate results will be reported in publications and trial registry updates.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .